Intercept Pharmaceuticals
Intercept Pharmaceuticals
Employees:
480
Market Cap:
$2.7 billion
Revenue:
$130.98 million
5 Year Trend:
121.6%
Net Income:
$-375.06 million
Stock:
ICPT

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. The companys lead product is Obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747. Wikipedia

Intercept Pharmaceuticals
Are you from Intercept Pharmaceuticals?

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. The companys lead product is Obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747. Wikipedia

Employees:
480
Market Cap:
$2.7 billion
Revenue:
$130.98 million
5 Year Trend:
121.6%
Net Income:
$-375.06 million
Stock:
ICPT

22 jobs at Intercept Pharmaceuticals

Jobs in